Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: A phase II trial

Supportive Care in Cancer

Volumn 20, Issue 10, 2012, Pages 2363-2369

  Abidi, Muneer H ^a,b   Tageja, Nishant ^a   Ayash, Lois ^a,b   Abrams, Judith ^a,b   Ratanatharathorn, Voravit ^a,b   Al Kadhimi, Zaid ^a,b   Lum, Lawrence ^a,b   Cronin, Simon ^b   Ventimiglia, Marie ^b   Uberti, Joseph ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Aprepitant; High dose cyclophosphamide; Nausea; Vomiting

Indexed keywords

APREPITANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANISETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL MOBILIZATION; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HICCUP; HUMAN; MALE; NAUSEA; NULL HYPOTHESIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL MOBILIZATION; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; RECOMBINANT PROTEINS; STEM CELL TRANSPLANTATION; VOMITING; YOUNG ADULT;

EID: 84868486373     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1341-3     Document Type: Article

References (24)

1. Morran C, Smith DC, Anderson DA (1979) Incidence of nausea and vomiting with cytotoxic chemotherapy: A prospective randomised trial of antiemetics. Br Med J 1:1323-1324 (Pubitemid 9172412)
2. Morrow GR, Lindke J, Black PM (1991) Predicting development of anticipatory nausea in cancer patients: Prospective examination of eight clinical characteristics. J Pain Symptom Manage 6:215- 223
3. Basch E, Prestrud AA, Hesketh PJ, Kris MG, et al. (2011) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol, September 26, 2011 [Epub ahead of print]
4. Diemunsch P, Grélot L (2000) Potential of substance P antagonists as antiemetics. Drugs 60:533-546
5. Gardner CJ, Bountra C, Bunce KT (1994) Anti-emetic activity of neurokinin NK1 receptor antagonists is mediated centrally in the ferret. Br J Pharmacol 112:516P
6. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090-3098 (Pubitemid 36676265)
7. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112-4119 (Pubitemid 46606178)
8. deWit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ (2003) Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatinbased chemotherapy. J Clin Oncol 21(22):4105-4111 (Pubitemid 46606177)
9. Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F, Aprepitant Moderately Emetogenic Chemotherapy Study Group (2006) Efficacy and tolerability of aprepitant for the prevention of chemotherapyinduced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 106(7):1641
10. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, ESMO/MASCC Guidelines Working Group (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232-v243
11. Merck and Co. Inc (2006) Aprepitant (Emend) package insert. Whitehouse Station, NJ
12. de Jonge ME, Huitema AD, Holtkamp MJ, van Dam SM, Beijnen JH, Rodenhuis S (2005) Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 56:370-378 (Pubitemid 41095400)
13. Bubalo JS, Cherala G, McCune JS, Munar MY, Tse S, Maziarz R (2011) Aprepitant Pharmacokinetics and Assessing the Impact of Aprepitant on Cyclophosphamide Metabolism in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation. J Clin Pharmacol. Mar 17. [Epub ahead of print]
14. Bashey A, Donohue M, Liu L, Medina B, Lane TA (2007) Peripheral blood progenitor cell mobilization with intermediatedose cyclophosphamide, sequential granulocyte-macrophagecolony- stimulating factor and granulocyte-colony- stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Transfusion 47 (11):2153-2160 (Pubitemid 47623985)
15. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Richardson PG, Durie BG, Rajkumar SV, International Myeloma Working Group (2009) Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomibcontaining regimens. Blood 114(9):1729-1735
16. Beck TM (1995) The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anticancer Drugs 6(2):237-242
17. Grunberg SM, Boutin N, Ireland A, Miner S, Silveira J, Ashikaga T (1996) Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer 4(6):435-439 (Pubitemid 126470385)
18. NCI CTC version 3. (http://ctep.cancer.gov/protocolDevelopment/ electronicapplications/docs/ctcaev3.pdf)
19. Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17(6):1000-1006 (Pubitemid 43778994)
20. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3(10):1379-1384 (Pubitemid 15244935)
21. Hesketh PJ, Van Belle S, Aapro M et al (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39:1074-1080 (Pubitemid 36555864)
22. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Malave JJ (1992) Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 66(1):198-203
23. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23 (24):5851
24. Stiff P, Fox-Geiman M, Kiley K, Porter N, Rychlik K, Fletcher-Gonzalez D, Toor A, Smith SE, Rodriguez T (2009) Aprepitant vs. placebo plus oral ondansetron and dexamethasone for the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to hematopoietic stem cell transplantation: a prospective, randomized doubleblind phase III trial. Blood (ASH Annual Meeting Abstracts) 114:2267